PMID- 32888285
OWN - NLM
STAT- MEDLINE
DCOM- 20220125
LR  - 20220125
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 21
IP  - 7
DP  - 2021
TI  - The Interaction between Arachidonic Acid Metabolism and Homocysteine.
PG  - 1232-1241
LID - 10.2174/1871530320999200904130504 [doi]
AB  - Hyperhomocysteinemia (HHcy) has been considered a risk factor for different 
      diseases, including cardiovascular disease (CVD), inflammation, neurological 
      diseases, cancer, and many other pathological conditions. Likewise, arachidonic 
      acid (AA) metabolism is implicated in both vascular homeostasis and inflammation, 
      as shown by the development of CVD, following the imbalance of its metabolites. 
      This review summarizes how homocysteine (Hcy) can influence the metabolism of AA. 
      In silico literature searches were performed on PubMed and Scopus as main 
      sources. Several studies have shown that altered levels of Hcy, through AA 
      release and metabolism, can influence the synthesis and the activity of 
      prostaglandins (PGs), prostacyclin (PGI2), thromboxane (TXA), epoxyeicosatrienoic 
      acids (EETs), and hydroxyeicosatetraenoic acids (HETEs). It is believed that by 
      targeting Hcy in the AA pathways, novel compounds with better pharmacological and 
      pharmacodynamics benefits may be obtained and that this information is valuable 
      for a dietician to manipulate diets to improve health.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Domi, Elisa
AU  - Domi E
AD  - Department of Chemical-Toxicological and Pharmacological Evaluation of Drugs, 
      Faculty of Pharmacy, Catholic University Our Lady of Good Counsel, Rruga Dritan 
      Hoxha, Tirana, Albania.
FAU - Hoxha, Malvina
AU  - Hoxha M
AD  - Department of Chemical-Toxicological and Pharmacological Evaluation of Drugs, 
      Faculty of Pharmacy, Catholic University Our Lady of Good Counsel, Rruga Dritan 
      Hoxha, Tirana, Albania.
FAU - Hoxha, Bianka
AU  - Hoxha B
AD  - Department of Chemical-Toxicological and Pharmacological Evaluation of Drugs, 
      Faculty of Pharmacy, Catholic University Our Lady of Good Counsel, Rruga Dritan 
      Hoxha, Tirana, Albania.
FAU - Zappacosta, Bruno
AU  - Zappacosta B
AD  - Department of Chemical-Toxicological and Pharmacological Evaluation of Drugs, 
      Faculty of Pharmacy, Catholic University Our Lady of Good Counsel, Rruga Dritan 
      Hoxha, Tirana, Albania.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 27YG812J1I (Arachidonic Acid)
SB  - IM
MH  - Animals
MH  - Arachidonic Acid/*blood
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/*blood/diagnosis/epidemiology
MH  - Heart Disease Risk Factors
MH  - Homocysteine/*blood
MH  - Humans
MH  - Hyperhomocysteinemia/*blood/diagnosis/epidemiology
MH  - Prognosis
MH  - Risk Assessment
OTO - NOTNLM
OT  - Homocysteine
OT  - arachidonic acid
OT  - cardiovascular diseases
OT  - epoxyeicosatrienoic acids
OT  - homeostasis.
OT  - hyperhomocysteinemia
EDAT- 2020/09/06 06:00
MHDA- 2022/01/27 06:00
CRDT- 2020/09/05 08:33
PHST- 2020/04/08 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2020/09/05 08:33 [entrez]
AID - EMIDDT-EPUB-109689 [pii]
AID - 10.2174/1871530320999200904130504 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2021;21(7):1232-1241. doi: 
      10.2174/1871530320999200904130504.